Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by M101on Jun 28, 2022 5:48pm
143 Views
Post# 34788844

RE:RE:RE:Worst management

RE:RE:RE:Worst management Elliot was a clown, but I don't know if Gene is still paying him.  When it mattered, Gene took the money up front knowing that it increased our risk of bankruptcy, so I'm going to assume he only appointed others of the same calibre, and it's still mostly his board.

As for the window, I guess that was ambiguous as your interpretation is not at all what I meant.
I was opining again about economy as I believe we have only started a multi-year bear market.

But I'm very optimistic that Promis has narrowly missed a tipping point into death spiral financing, and looking back that point was when Elliot announced his retirement. 
<< Previous
Bullboard Posts
Next >>